Form 4: Director Lance Berry Receives RSU Grant at Treace Medical

Director Lance A. Berry was granted 30,000 restricted stock units (RSUs) by Treace Medical Concepts, Inc. on May 19, 2026.

Summary

• Director Lance A. Berry acquired 30,000 restricted stock units (RSUs) of Treace Medical Concepts, Inc. (TMCI).
• The RSUs represent a right to receive one share of common stock per unit upon vesting.
• Vesting is scheduled for the earlier of May 19, 2027, or the 2027 annual meeting of stockholders, contingent on continued service.
• The reporting person has elected to defer receipt of the underlying shares until a change in control or separation of service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None noted.

Risks

• Vesting is subject to the director's continued service to the issuer.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice to ensure alignment between leadership and shareholders in the medical device sector.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with standard practices for publicly traded medical technology companies.
• The deferral election is a common tax and estate planning strategy utilized by corporate directors.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of RSUs on May 19, 2027, or the 2027 annual meeting of stockholders.

Key Dates

Keywords

Treace Medical Concepts, TMCI, Form 4, Insider Trading, Restricted Stock Units, Director Compensation